Tocilizumab Promising for sJIA
- Tweet
You Might Also Like:
- FDA Approves Subcutaneous Tocilizumab for Ages 2–17
- E6011 & Tocilizumab Monotherapy Studies Show Promising Results for RA Patients
- Rheumatology Drug Updates: Abaloparatide Promising for Osteoporosis, Plus Secukinumab for Ankylosing Spondylitis
- Upadacitinib Monotherapy Proves Promising; Plus FDA Approves Tocilizumab Autoinjector